Cantex Pharmaceuticals
Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 that develops novel and safer cancer treatments by repositioning known therapies, operating from Weston, United States with a 1-10 employee team.
- Company typePrivate
- Founded2002
- HeadquartersWeston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cantex Pharmaceuticals does
Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 and headquartered in Weston, United States, with a reported headcount of 1-10 employees. The company's stated mission is to harness known therapies to develop novel and safer cancer treatments, indicating a drug repositioning/reformulation strategy that leverages existing pharmacology and safety data to accelerate oncology product development. Its core products are not enumerated in available disclosures, but the positioning implies investigational oncology candidates built around repurposed or modified known agents, advanced through regulatory and clinical milestones typical of small-molecule or biologic oncology programs. The business model is consistent with a venture-backed clinical-stage biotech: revenue is generated, if at all, through licensing, milestone payments, or partnerships with larger pharmaceutical companies rather than direct product sales, and the company has raised approximately $33.6 million across six funding rounds from 2002 to 2014 from specialized biotech investors including CHL Medical Partners, Domain Associates, Research Corporation Technologies, The Aurora Funds, and Venture Academy. Leadership is concentrated in a two-person executive team — Stephen Marcus (CEO) and Gregory Johnson (COO) — and the company operates without disclosed commercial infrastructure, pricing, distribution channels, or named customers in the available data set.
Cantex Pharmaceuticals firmographics
Firmographics- Name
- Cantex Pharmaceuticals
- Website
- https://cantex.com
- Company type
- Private
- Founded year
- 2002
- Headcount range
- 1–10 employees
- Short description
- Cantex Pharmaceuticals is a privately held, clinical-stage biotechnology company founded in 2002 that develops novel and safer cancer treatments by repositioning known therapies, operating from Weston, United States with a 1-10 employee team.
- Ownership category
- akta.pro rank
Cantex Pharmaceuticals industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Cantex Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Weston
- HQ country
- United States
- HQ region
- North America
Markets served
Cantex Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Cantex Pharmaceuticals product offering
Product offeringCore offering
Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. The company focuses on oncology drug development, leveraging existing therapeutic modalities to create improved cancer treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel cancer therapeutics pipeline Development of novel and safer cancer treatments through repositioning of known therapies; intended for oncology pharmaceutical partners and ultimately cancer patients.
Companies that use Cantex Pharmaceuticals
Customer profileIdeal customer profiles1 record
Cantex Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cantex Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights2 records
Cantex Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- MacroGenics: Clinical-stage biopharmaceutical company developing monoclonal antibodies for cancer treatment. Operates in the same oncology drug development space with comparable mid-stage programs.
- Aprea Therapeutics: Clinical-stage biotech developing novel cancer therapies targeting specific tumor suppressor pathways. Comparable in scale and clinical-stage oncology development to Cantex.
- Moleculin Biotech: Small-cap clinical-stage oncology biotech developing repurposed and novel drug candidates. Comparable to Cantex in scale, therapeutic focus, and development-stage profile.
- MEI Pharma: Oncology-focused specialty pharmaceutical company developing differentiated therapies for cancer. Operates in the same oncology specialty pharma category as Cantex with similar patient-focused positioning.
- Verastem Oncology: Clinical-stage oncology company developing drugs to improve outcomes for patients with cancer. Similar size and focus on developing targeted oncology therapeutics.
Broad incumbents
- ImmunoGen: Established oncology biotech developing antibody-drug conjugates for cancer. A larger incumbent operating in Cantex's oncology therapeutic area with overlapping patient populations.
- Spectrum Pharmaceuticals: Commercial-stage oncology and hematology specialty pharma. Larger, more diversified incumbent in the same oncology specialty pharmaceutical space as Cantex.
- Puma Biotechnology: Established oncology specialty pharma focused on developing and commercializing novel cancer therapies. A broader, more advanced incumbent operating in Cantex's target therapeutic area.
- Clovis Oncology: Specialty oncology company focused on acquiring, developing, and commercializing anti-cancer agents. A more mature oncology specialty pharma comparable in therapeutic focus.
Emerging players
- Biovie: Small-cap biotech focused on drug repurposing in oncology and other diseases. Directly comparable strategy to Cantex's known-therapy repositioning approach.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
Cantex Pharmaceuticals social profiles
Digital presenceCantex Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cantex Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Cantex Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cantex Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cantex Pharmaceuticals
What does Cantex Pharmaceuticals do?
Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. The company focuses on oncology drug development, leveraging existing therapeutic modalities to create improved cancer treatments.
When was Cantex Pharmaceuticals founded?
Cantex Pharmaceuticals was founded in 2002. It employs 1 to 10 people.
Where is Cantex Pharmaceuticals based?
Cantex Pharmaceuticals is headquartered in Weston, United States, in the North America region.
Who are Cantex Pharmaceuticals's main competitors?
Direct peers on record are MacroGenics, Aprea Therapeutics, Moleculin Biotech, MEI Pharma and Verastem Oncology. Broad incumbents are ImmunoGen, Spectrum Pharmaceuticals, Puma Biotechnology and Clovis Oncology. Biovie is listed as an emerging player.
Does Cantex Pharmaceuticals have an API?
No public API is recorded for Cantex Pharmaceuticals.
What industry is Cantex Pharmaceuticals in?
Cantex Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.